Drug intelligence / Profile preview

SYP-2590

Development stage: Preclinical
Lead developer: Samyang Holdings Biopharm Group
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems

Overview

SYP-2590 is an mRNA-based therapeutic candidate being developed by Samyang Holdings Biopharm Group for the treatment of idiopathic pulmonary fibrosis (IPF). The drug utilizes Samyang's proprietary SENS™ (Samyang Elucidative Nanoparticle System) delivery technology, which employs specialized nanoparticles to protect and deliver mRNA to target tissues. While the specific protein encoded by the mRNA has not been publicly disclosed, the therapy is designed to address the underlying pathophysiology of lung fibrosis by inducing the expression of therapeutic proteins directly within the lung environment. It is currently in the preclinical stage of development.

Beyond the preview

Go deeper on SYP-2590.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYP-2590.

Explore the full profile